Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas

Gustavo Pradilla, Federico G. Legnani, Giovanna Petrangolini, Pierangelo Francescato, Francesco Chillemi, Betty M. Tyler, Sergio M. Gaini, Henry Brem, Alessandro Olivi, Francesco DiMeco

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

OBJECTIVE: Endostatin is an anti-angiogenic agent that blocks matrix-metalloproteinase-2 and inhibits endothelial cell proliferation. Currently, endostatin is available through recombinant technology, which limits its broader use. In this study, a synthetic endostatin fragment (EF) was analyzed to determine its anti-angiogenic properties when locally delivered by controlled-release polymers and to establish its effect as a treatment for experimental gliomas. METHODS: Cytotoxicity of EF against 9L gliosarcoma and F98 glioma was determined in vitro. EF was loaded into polyanhydride-poly-(bis- [carboxyphenoxy-propane]-sebacic-acid) (pCPP:SA) polymers at increasing concentrations. Pharmacokinetics of the EF/polymer formulations were defined in vitro. Anti-angiogenic properties of the EF/polymer formulations were evaluated in the rat-cornea micropocket assay. Toxicity and efficacy of locally delivered EF polymers either alone or combined with systemic bischloroethylnitrosourea (carmustine) were determined in rats intracranially challenged with 9L gliosarcoma. RESULTS: EF showed scarce cytotoxicity against 9L and F98 in vitro. EF/pCPP:SA formulations showed sustained release by day 19. Mean corneal angiogenesis index 20 days after tumor implantation was 4.5 ± 0.7 for corneas implanted with 40% EF/pCPP:SA compared with controls (8.5 ± 1.3, P = 0.02). Intracranial efficacy studies showed that EF polymers alone did not prolong animal survival. Combination of 40% EF/pCPP:SA polymers with systemic bischloroethylnitrosourea (carmustine) prolonged survival (median survival of 44 d, P = 0.001) and generated 33% long-term survivors. CONCLUSION: Controlled-release polymers can effectively deliver a biologically active EF in a sustained fashion. EF inhibits angiogenesis in vitro and in vivo, and even though EF does not prolong survival as a single agent, it exhibits a synergistic effect when combined with systemic bischloroethylnitrosourea (carmustine) in the intracranial 9L gliosarcoma model.

Original languageEnglish
Pages (from-to)1032-1040
Number of pages9
JournalNeurosurgery
Volume57
Issue number5
DOIs
Publication statusPublished - Nov 2005

Fingerprint

Endostatins
Glioma
Polymers
Gliosarcoma
Carmustine
Cornea
Survival
Polyanhydrides
Corneal Neovascularization
Propane
Matrix Metalloproteinase 2

Keywords

  • Brain tumor
  • Controlled-release
  • Endostatin
  • Gliomas
  • Local delivery polymer

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas. / Pradilla, Gustavo; Legnani, Federico G.; Petrangolini, Giovanna; Francescato, Pierangelo; Chillemi, Francesco; Tyler, Betty M.; Gaini, Sergio M.; Brem, Henry; Olivi, Alessandro; DiMeco, Francesco.

In: Neurosurgery, Vol. 57, No. 5, 11.2005, p. 1032-1040.

Research output: Contribution to journalArticle

Pradilla, G, Legnani, FG, Petrangolini, G, Francescato, P, Chillemi, F, Tyler, BM, Gaini, SM, Brem, H, Olivi, A & DiMeco, F 2005, 'Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas', Neurosurgery, vol. 57, no. 5, pp. 1032-1040. https://doi.org/10.1227/01.NEU.0000180059.33665.c1
Pradilla, Gustavo ; Legnani, Federico G. ; Petrangolini, Giovanna ; Francescato, Pierangelo ; Chillemi, Francesco ; Tyler, Betty M. ; Gaini, Sergio M. ; Brem, Henry ; Olivi, Alessandro ; DiMeco, Francesco. / Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas. In: Neurosurgery. 2005 ; Vol. 57, No. 5. pp. 1032-1040.
@article{4911e438572d441e92ae9974cb7fc7c8,
title = "Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas",
abstract = "OBJECTIVE: Endostatin is an anti-angiogenic agent that blocks matrix-metalloproteinase-2 and inhibits endothelial cell proliferation. Currently, endostatin is available through recombinant technology, which limits its broader use. In this study, a synthetic endostatin fragment (EF) was analyzed to determine its anti-angiogenic properties when locally delivered by controlled-release polymers and to establish its effect as a treatment for experimental gliomas. METHODS: Cytotoxicity of EF against 9L gliosarcoma and F98 glioma was determined in vitro. EF was loaded into polyanhydride-poly-(bis- [carboxyphenoxy-propane]-sebacic-acid) (pCPP:SA) polymers at increasing concentrations. Pharmacokinetics of the EF/polymer formulations were defined in vitro. Anti-angiogenic properties of the EF/polymer formulations were evaluated in the rat-cornea micropocket assay. Toxicity and efficacy of locally delivered EF polymers either alone or combined with systemic bischloroethylnitrosourea (carmustine) were determined in rats intracranially challenged with 9L gliosarcoma. RESULTS: EF showed scarce cytotoxicity against 9L and F98 in vitro. EF/pCPP:SA formulations showed sustained release by day 19. Mean corneal angiogenesis index 20 days after tumor implantation was 4.5 ± 0.7 for corneas implanted with 40{\%} EF/pCPP:SA compared with controls (8.5 ± 1.3, P = 0.02). Intracranial efficacy studies showed that EF polymers alone did not prolong animal survival. Combination of 40{\%} EF/pCPP:SA polymers with systemic bischloroethylnitrosourea (carmustine) prolonged survival (median survival of 44 d, P = 0.001) and generated 33{\%} long-term survivors. CONCLUSION: Controlled-release polymers can effectively deliver a biologically active EF in a sustained fashion. EF inhibits angiogenesis in vitro and in vivo, and even though EF does not prolong survival as a single agent, it exhibits a synergistic effect when combined with systemic bischloroethylnitrosourea (carmustine) in the intracranial 9L gliosarcoma model.",
keywords = "Brain tumor, Controlled-release, Endostatin, Gliomas, Local delivery polymer",
author = "Gustavo Pradilla and Legnani, {Federico G.} and Giovanna Petrangolini and Pierangelo Francescato and Francesco Chillemi and Tyler, {Betty M.} and Gaini, {Sergio M.} and Henry Brem and Alessandro Olivi and Francesco DiMeco",
year = "2005",
month = "11",
doi = "10.1227/01.NEU.0000180059.33665.c1",
language = "English",
volume = "57",
pages = "1032--1040",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas

AU - Pradilla, Gustavo

AU - Legnani, Federico G.

AU - Petrangolini, Giovanna

AU - Francescato, Pierangelo

AU - Chillemi, Francesco

AU - Tyler, Betty M.

AU - Gaini, Sergio M.

AU - Brem, Henry

AU - Olivi, Alessandro

AU - DiMeco, Francesco

PY - 2005/11

Y1 - 2005/11

N2 - OBJECTIVE: Endostatin is an anti-angiogenic agent that blocks matrix-metalloproteinase-2 and inhibits endothelial cell proliferation. Currently, endostatin is available through recombinant technology, which limits its broader use. In this study, a synthetic endostatin fragment (EF) was analyzed to determine its anti-angiogenic properties when locally delivered by controlled-release polymers and to establish its effect as a treatment for experimental gliomas. METHODS: Cytotoxicity of EF against 9L gliosarcoma and F98 glioma was determined in vitro. EF was loaded into polyanhydride-poly-(bis- [carboxyphenoxy-propane]-sebacic-acid) (pCPP:SA) polymers at increasing concentrations. Pharmacokinetics of the EF/polymer formulations were defined in vitro. Anti-angiogenic properties of the EF/polymer formulations were evaluated in the rat-cornea micropocket assay. Toxicity and efficacy of locally delivered EF polymers either alone or combined with systemic bischloroethylnitrosourea (carmustine) were determined in rats intracranially challenged with 9L gliosarcoma. RESULTS: EF showed scarce cytotoxicity against 9L and F98 in vitro. EF/pCPP:SA formulations showed sustained release by day 19. Mean corneal angiogenesis index 20 days after tumor implantation was 4.5 ± 0.7 for corneas implanted with 40% EF/pCPP:SA compared with controls (8.5 ± 1.3, P = 0.02). Intracranial efficacy studies showed that EF polymers alone did not prolong animal survival. Combination of 40% EF/pCPP:SA polymers with systemic bischloroethylnitrosourea (carmustine) prolonged survival (median survival of 44 d, P = 0.001) and generated 33% long-term survivors. CONCLUSION: Controlled-release polymers can effectively deliver a biologically active EF in a sustained fashion. EF inhibits angiogenesis in vitro and in vivo, and even though EF does not prolong survival as a single agent, it exhibits a synergistic effect when combined with systemic bischloroethylnitrosourea (carmustine) in the intracranial 9L gliosarcoma model.

AB - OBJECTIVE: Endostatin is an anti-angiogenic agent that blocks matrix-metalloproteinase-2 and inhibits endothelial cell proliferation. Currently, endostatin is available through recombinant technology, which limits its broader use. In this study, a synthetic endostatin fragment (EF) was analyzed to determine its anti-angiogenic properties when locally delivered by controlled-release polymers and to establish its effect as a treatment for experimental gliomas. METHODS: Cytotoxicity of EF against 9L gliosarcoma and F98 glioma was determined in vitro. EF was loaded into polyanhydride-poly-(bis- [carboxyphenoxy-propane]-sebacic-acid) (pCPP:SA) polymers at increasing concentrations. Pharmacokinetics of the EF/polymer formulations were defined in vitro. Anti-angiogenic properties of the EF/polymer formulations were evaluated in the rat-cornea micropocket assay. Toxicity and efficacy of locally delivered EF polymers either alone or combined with systemic bischloroethylnitrosourea (carmustine) were determined in rats intracranially challenged with 9L gliosarcoma. RESULTS: EF showed scarce cytotoxicity against 9L and F98 in vitro. EF/pCPP:SA formulations showed sustained release by day 19. Mean corneal angiogenesis index 20 days after tumor implantation was 4.5 ± 0.7 for corneas implanted with 40% EF/pCPP:SA compared with controls (8.5 ± 1.3, P = 0.02). Intracranial efficacy studies showed that EF polymers alone did not prolong animal survival. Combination of 40% EF/pCPP:SA polymers with systemic bischloroethylnitrosourea (carmustine) prolonged survival (median survival of 44 d, P = 0.001) and generated 33% long-term survivors. CONCLUSION: Controlled-release polymers can effectively deliver a biologically active EF in a sustained fashion. EF inhibits angiogenesis in vitro and in vivo, and even though EF does not prolong survival as a single agent, it exhibits a synergistic effect when combined with systemic bischloroethylnitrosourea (carmustine) in the intracranial 9L gliosarcoma model.

KW - Brain tumor

KW - Controlled-release

KW - Endostatin

KW - Gliomas

KW - Local delivery polymer

UR - http://www.scopus.com/inward/record.url?scp=27644433598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644433598&partnerID=8YFLogxK

U2 - 10.1227/01.NEU.0000180059.33665.c1

DO - 10.1227/01.NEU.0000180059.33665.c1

M3 - Article

VL - 57

SP - 1032

EP - 1040

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 5

ER -